Metabolic
CagriSema
Also called Semaglutide + cagrilintide, Cagrilintide/semaglutide 2.4/2.4
per administration
A human trial worked out how much to take and how often, so a dosing schedule is shown.
Work out your draw
These numbers are a starting point — change any of them.
- Concentration
- 1.6mg/mL
- Volume per draw
- 0.31mL
- Units to dial
- 31
- Doses per cartridge
- 9
Requested 0.313 mL
Requested 31.25
31.25 units is between clicks. The nearest setting is 31, which delivers 496 mcg instead of 500 mcg.
Vial label
Copy this into your label printer.
What one draw delivers
| Component | Share | Per draw |
|---|---|---|
| Semaglutide | 50% | 250 mcg |
| Cagrilintide | 50% | 250 mcg |
Every draw has these same proportions.
0.5–4.8 mg of CagriSema per administration, worked out from the components rather than quoted from a study of the blend.
A fixed-ratio blend of semaglutide and cagrilintide sold as one vial, so it is drawn as a whole. The two clear at different multi-day rates, so no single half-life is given and the decay view plots both components. The range here is worked out from the components rather than quoted as one figure: escalation mirrors semaglutide's weekly steps to a combined 2.4 mg + 2.4 mg. Its components are covered on their own pages.
What is in a 4.8 mg CagriSema vial
| Component | Share | Per vial |
|---|---|---|
| Semaglutide | 50% | 2.4 mg |
| Cagrilintide | 50% | 2.4 mg |
Every draw has these same proportions.
Dosing schedule
How CagriSema is commonly stepped up, for reference only.
These are commonly-discussed research protocols shared for educational reference. This is not medical advice and is not a substitute for guidance from a qualified professional.
| Phase | Amount | Frequency | Route |
|---|---|---|---|
| Weeks 1–4Semaglutide + cagrilintide; conservative start to limit gastrointestinal effects. | 0.25 mg + 0.25 mg | Once weekly | SubQ |
| Weeks 5–8 | 0.5 mg + 0.5 mg | Once weekly | SubQ |
| Weeks 9–12 | 1.0 mg + 1.0 mg | Once weekly | SubQ |
| Weeks 13–16 | 1.7 mg + 1.7 mg | Once weekly | SubQ |
| Week 17+Target combined step; step up no sooner than every 4 weeks. | 2.4 mg + 2.4 mg | Once weekly | SubQ |
Modelled level — once a week
One curve per component: the components clear at very different rates.
Where these numbers come from
- REDEFINE 1 (Novo Nordisk phase-3 obesity program)Once-weekly semaglutide 2.4 mg co-formulated with cagrilintide 2.4 mg (CagriSema) escalated over 16 weeks in adults with obesity.
- Component sourcesSee the semaglutide and cagrilintide pages for the individual components' trials.